886 Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures

• Phuong Nguyen,
• Igor Feldman,
• Mohammad Zafari,
• Ryan Phennicie,
• Veronica Komoroski,
• Steve Sazinsky,
• Joe Wahle,
• Denise Manfra,
• Tatiana Novobrantseva,
• Kathryn Rooney,
• Craig Mizzoni,
• Boris Klebanov,
• Jessica Ritter

Affiliations

Phuong Nguyen

Deakin Health Economics, Deakin University Faculty of Health, Burwood, Victoria, Australia

Igor Feldman

Aff1 Jounce Therapeutics Cambridge MA USA

Mohammad Zafari

Aff1 Jounce Therapeutics Cambridge MA USA

Ryan Phennicie

1Verseau Therapeutics, Bedford, MA, USA

Veronica Komoroski

1Verseau Therapeutics, Bedford, MA, USA

Steve Sazinsky

1Verseau Therapeutics, Bedford, MA, USA

Joe Wahle

1Verseau Therapeutics, Bedford, MA, USA

Denise Manfra

1Verseau Therapeutics, Bedford, MA, USA

Tatiana Novobrantseva

1Verseau Therapeutics, Bedford, MA, USA

Kathryn Rooney

Verseau Therapeutics, Bedford, MA, USA

Craig Mizzoni

Verseau Therapeutics, Bedford, MA, USA

Boris Klebanov

Verseau Therapeutics, Bedford, MA, USA

Jessica Ritter

Verseau Therapeutics, Bedford, MA, USA